Softwr

Healthcare · head to head

Ibex Medical Analytics vs Paige

Ibex Medical Analytics logo

Ibex Medical Analytics

Healthcare

Cancer detection AI for breast, prostate and gastric pathology deployed in routine clinical service, not just pilots

From
On request
Rated
-
Full reviewWebsite
Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Ibex Medical Analytics the European IVDR indication is broader than the United States position, where some applications operate under laboratory developed test arrangements rather than FDA authorisation, which determines whether AI output can influence a signed report.; Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • They diverge on capability: Ibex Medical Analytics covers Ibex Breast Suite, Paige covers Paige Prostate Detect.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Ibex Medical Analytics and Paige actually diverge.

Attributes where Ibex Medical Analytics and Paige differ
AttributeIbex Medical AnalyticsPaige

Identical on both: starting price (On request), pricing model (quote), free tier (No), platforms (Web, Cloud, On-premise), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Ibex Medical Analytics

  • Ibex Breast Suite
  • Ibex Prostate
  • Ibex Gastric
  • Second read safety net
  • Prescreening triage
  • Heatmap localisation
  • Quality reporting
  • Scanner-agnostic ingestion

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

What people use each for

The jobs each tool is most often brought in to do.

Ibex Medical Analytics

  • A histopathology department that cannot recruit and wants an automated safety net on every prostate and breast biopsy before sign outnot Paige
  • A private laboratory group standardising Gleason grading across pathologists with known interobserver variabilitynot Paige
  • A service digitising histopathology that needs a clinical governance argument to justify the scanning programme to its boardnot Paige
  • A gastrointestinal service wanting Helicobacter pylori detection automated so pathologists spend their time on the neoplastic casesnot Paige

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Ibex Medical Analytics
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Ibex Medical Analytics
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Ibex Medical Analytics
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Ibex Medical Analytics

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Ibex Medical Analytics

  • The European IVDR indication is broader than the United States position, where some applications operate under laboratory developed test arrangements rather than FDA authorisation, which determines whether AI output can influence a signed report.
  • It requires a fully digitised histopathology workflow, and slide scanning, storage and validation typically cost several times the algorithm licence.
  • Running it as a second read safety net adds a discrepancy resolution workload that departments consistently underestimate, and someone senior has to adjudicate every flag.
  • Coverage is limited to breast, prostate and gastric, so a general histopathology department still reads the majority of its case mix without any AI support.
  • Pricing is per case and unpublished, so cost scales directly with biopsy volume and does not flatten as the department grows.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Pricing, plan by plan

Ibex Medical Analytics

On request
  • Ibex clinical applications$undefined/year
    • Priced per case analysed under an annual agreement
    • Breast, prostate and gastric licensed as separate suites
    • Regulatory indication differs between Europe and the United States

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Which should you pick?

Choose Ibex Medical Analytics if

  • You need ibex breast suite.
  • You work on Web, Cloud, On-premise.
  • You also want ibex prostate.
Ibex Medical Analytics review

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Questions people ask

Is Ibex Medical Analytics or Paige better?
Neither clearly leads. Ibex Medical Analytics starts at On request and Paige at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Ibex Medical Analytics or Paige?
Ibex Medical Analytics starts at On request and Paige at On request.
Does Ibex Medical Analytics or Paige run on more platforms?
Both run on Web, Cloud, On-premise, so platform support will not decide this one for you.
What is Ibex Medical Analytics best used for?
Ibex Medical Analytics is most often used for a histopathology department that cannot recruit and wants an automated safety net on every prostate and breast biopsy before sign out, a private laboratory group standardising gleason grading across pathologists with known interobserver variability, a service digitising histopathology that needs a clinical governance argument to justify the scanning programme to its board, a gastrointestinal service wanting helicobacter pylori detection automated so pathologists spend their time on the neoplastic cases. Of those, a histopathology department that cannot recruit and wants an automated safety net on every prostate and breast biopsy before sign out and a private laboratory group standardising gleason grading across pathologists with known interobserver variability are not what Paige is typically brought in for.
What can Ibex Medical Analytics do that Paige cannot?
Ibex Medical Analytics covers Ibex Breast Suite, Ibex Prostate, Ibex Gastric, Second read safety net. Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

Ibex Medical Analytics: Is Ibex FDA cleared?

The regulatory position differs by product and market. In Europe the products carry CE marking under IVDR for defined diagnostic indications; in the United States some applications are used under laboratory developed test arrangements. Confirm the exact status for the specific application and market before assuming it can influence a signed report.

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Ibex Medical Analytics: Second read or prescreening?

Both are supported. Second read as a safety net is the more common clinical governance justification; prescreening is the efficiency case.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Ibex Medical Analytics: Does it need a particular scanner?

It ingests from the major whole slide scanner vendors rather than requiring a single fleet, which is a practical advantage over vendors tied to one scanner.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Ibex Medical Analytics: What tissue types are covered?

Breast, prostate and gastric. Everything else in the case mix is unsupported.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on Ibex Medical Analytics

More on Paige

Keep looking

Other head to heads